SenesTech Inc (SNES) Receives Average Recommendation of “Strong Buy” from Analysts
SenesTech Inc (NASDAQ:SNES) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus target price of $2.50 for the company and are anticipating that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also assigned SenesTech an industry rank of 106 out of 255 based on the ratings given to related companies.
Separately, Zacks Investment Research raised shares of SenesTech from a “sell” rating to a “hold” rating in a research note on Saturday, June 30th.
SenesTech (NASDAQ:SNES) last posted its quarterly earnings results on Monday, August 13th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.40 million. SenesTech had a negative return on equity of 214.75% and a negative net margin of 13,362.22%. As a group, equities analysts expect that SenesTech will post -0.61 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in SenesTech stock. Bank of Montreal Can purchased a new position in SenesTech Inc (NASDAQ:SNES) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 80,000 shares of the company’s stock, valued at approximately $131,000. Bank of Montreal Can owned about 0.48% of SenesTech as of its most recent SEC filing. 8.03% of the stock is owned by hedge funds and other institutional investors.
SenesTech Company Profile
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Recommended Story: Return on Equity (ROE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.